[Mexiletine in the treatment of lidocaine-resistant ventricular tachycardia. Preliminary results].
Intravenous mexiletine (3 mg/Kg as bolus) was given to 7 patients with sustained ventricular tachycardia. Previous lidocaine administration in standard doses failed to suppress ventricular tachycardia. Mexiletine successfully suppressed the episodes of ventricular tachycardia in 6 of the 7 patients at a dose of 250 mg. Minimal non-cardiac toxicity occurred after mexiletine administration in the majority of patients. Mexiletine appears to be a promising alternative to lidocaine in the management of ventricular arrhythmias.
D004351:Drug Resistance; D005260:Female; D006801:Humans; D008012:Lidocaine / Q000627:therapeutic use; D008297:Male; D008801:Mexiletine / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000150:complications; D011437:Propylamines / Q000627:therapeutic use*; D013610:Tachycardia / Q000188:drug therapy* / Q000209:etiology; D013614:Tachycardia, Paroxysmal / Q000188:drug therapy
D011437:Propylamines; D008801:Mexiletine; D008012:Lidocaine
Efficacia del mexiletine nel trattamento delle tachicardie ventricolari resistenti alla lidocaina. Risultati preliminari.